SCHEMBL4831220

SCHEMBL4831220

COC(=O)C(CCc1ccccc1)CC(=O)OC(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSK P43235 2/20 0.46
CTSS P25774 1/20 0.46
KMT2A Q03164 1/20 0.46
ITGA4 P13612 1/20 0.44
ITGB7 P26010 1/20 0.44
KLK5 Q9Y337 2/20 0.43
CA2 P00918 1/20 0.43
CA9 Q16790 1/20 0.43
CTSG P08311 3/20 0.41
CTRB1 P17538 3/20 0.41
PRSS1 P07477 2/20 0.41
CMA1 P23946 2/20 0.41
TSHR P16473 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MMP1 P03956 1/20 0.40
MMP3 P08254 1/20 0.40
MMP9 P14780 1/20 0.40
ADRB2 P07550 1/20 0.40
ADRB1 P08588 1/20 0.40
ADRB3 P13945 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9574058 1.00 CTSK (0.46) CTSKCTSSKMT2AITGA4ITGB7
SCHEMBL8219512 0.88 SYK (0.44) CTSKCTSSCA2CA9
SCHEMBL8219511 0.88 SYK (0.44) CTSKCTSSCA2CA9
SCHEMBL1914954 0.87 CTSS (0.46) CTSKCTSSCA2CA9CTSG
SCHEMBL1915090 0.87 CTSS (0.46) CTSKCTSSCA2CA9CTSG
SCHEMBL1914958 0.87 CTSS (0.46) CTSKCTSSCA2CA9CTSG
SCHEMBL27680894 0.87 KMT2A (0.51) KMT2ACA9CTSGCTRB1TSHR
SCHEMBL27680893 0.87 KMT2A (0.51) KMT2ACA9CTSGCTRB1TSHR
SCHEMBL1915701 0.86 CA2 (0.52) CTSKCTSSKMT2AITGA4ITGB7
SCHEMBL1915705 0.86 CA2 (0.52) CTSKCTSSKMT2AITGA4ITGB7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7365091-B2 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX ENOBIA PHARMA (CA) 2008-04-29 US disclosed
US-20060287280-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX ENOBIA PHARMA (CA) 2006-12-21 US disclosed
US-7105539-B2 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex ENOBIA PHARMA (CA) 2006-09-12 US disclosed
US-20060135480-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex ENOBIA PHARMA (CA) 2006-06-22 US disclosed
EP-1572645-A2 DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX Enobia Pharma Inc. (CA) 2005-09-14 EP disclosed
US-20040186301-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex BIOMEP INC. 2004-09-23 US disclosed
WO-2004050620-A2 DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX ENOBIA PHARMA (CA) 2004-06-17 WO disclosed
EP-0561758-A2 Method of preparing optically active homo-beta-amino acids MONSANTO COMPANY (US) 1993-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060287280-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX GLS, SUCNR1, PGD CTSK 2373/4885CTSS 1630/4885KMT2A 2453/4885
US-20040186301-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex GLS, SUCNR1, PGD CTSK 2501/4885CTSS 1756/4885KMT2A 2577/4885
US-20060135480-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex GLS, SUCNR1, GCDH CTSK 2579/4885CTSS 1908/4885KMT2A 2487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.